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Abstract
Background: Cardiovascular disease (CVD) remains the largest cause of death in breast cancer survivors. The aim of
this study was to explore the impact of exercise intensity on aerobic fitness and autonomic cardiac regulation
(heart rate variability (HRV)) and salivary biomarkers of the stress systems (HPA-axis, cortisol; sympathetic nervous
system, α-amylase) and mucosal immunity (secretory(s)-IgA), markers of increased risk of CVD in breast cancer
survivors.
Methods: Participants were randomly assigned to; 1) high intensity interval training (HIIT); 2) moderate-intensity,
continuous aerobic training (CMIT); or 3) a wait-list control (CON) for a 12-week (36 session) stationary cycling
intervention. Cardiorespiratory fitness (VO2peak), resting HRV and salivary biomarkers were measured at baseline 2–4
d pre-intervention and 2–4 d post the last exercise session.
Results: Seventeen participants were included in this study (62 ± 8 years, HIIT; n = 6, CMIT; n = 5, CON; n = 6). A
significant improvement (p ≤ 0.05) was observed for VO2peak in the HIIT group; 19.3% (B = 3.98, 95%CI = [1.89; 4.02])
and a non-significant increase in the CMIT group; 5.6% (B = 1.96, 95%CI = [− 0.11; 4.03]), compared with a 2.6% (B =
− 0.64, 95%CI = [− 2.10; 0.82]) decrease in the CON group. Post intervention improvements in HRV markers of vagal
activity (log (ln)LF/HF, LnRMSSD) and sympathetic nervous system (α-amylase waking response) occurred for
individuals exhibiting outlying (> 95% CI) levels at baseline compared to general population.
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Conclusion: High intensity interval training improved cardiovascular fitness in breast cancer survivors and improved
cardiac regulation, and sympathetic nervous system (stress) responses in some individuals. High-intensity interval
training was safe and effective for breast cancer survivors to participate in with promising results as a time efficient
intensity to improve physical health and stress, reducing CVD risk.
Trial registration: This pilot study was retrospectively registered through the Australian New Zealand Clinical Trials
Registry (ANZCTR): ACTRN12620000684921.
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Background
Cardiovascular disease (CVD) remains the largest cause
of death in breast cancer survivors [1]. Exercise has been
shown to reduce both physiological and psychological
stress as well as CVD risk in cancer, but the specific
dose and intensity of exercise required to elicit these
benefits is unclear [2–4]. Breast cancer is the leading
cause of death in women aged 20–50 years, with diagno-
sis numbers growing each year [5]. The World Health
Organization (WHO) reported 2.08 million cases of
breast cancer worldwide in 2019, a major contributor to
the global burden of disease [6]. Women diagnosed with
breast cancer often experience complications after sur-
gery such as breast cancer related lymphoedema, axillary
web syndrome, and cancer-related fatigue [7–9]. They
also commonly suffer from long term treatment related
side effects such as peripheral neuropathies and reduced
quality of life [7, 10–13]. These side effects mean that
women with breast cancer often present with low base-
line fitness, strength, and quality of life (QoL) and could
achieve large physiological and psychological adaptations
from performing regular exercise, translating into a re-
duction in risk factors for CVD [14–16] and better
health outcomes.
Chronic stress has been defined as a maladaptive state
that is associated with altered immunity, hypothalamic
pituitary adrenal (HPA) axis, and autonomic nervous
system (ANS) functioning [17]. Both the independent
and interactive effects of the immune system, HPA axis
and ANS are key to understanding adaptive and mal-
adaptive psychological and physiological responses to
stress [18–20]. While research is still limited, HPA axis
and ANS dysfunction, as well as suppression of immun-
ity and low-grade inflammation are associated with in-
creased CVD risk, depression and mortality in breast
cancer survivors [21–23].
Protection from pathogens may be compromised in
cancer patients for whom radiation, chemotherapy, sur-
gery or effects induced by the cancer itself lead to im-
munosuppression [24–28]. Immunity, specifically cell-
mediated immunity, is critical for defence against some
types of tumours and has been shown to be decreased in
metastatic breast cancer patients, related to a
dysfunctional HPA axis (our central stress response sys-
tem) [23]. In addition, older people are less resistant to
pathogenic microorganisms, as they experience age-
related decreases to immune function [29]. Research has
shown that regular exercise can stimulate the immune
system in older people, which increases resistance to in-
fections [30–32]. In addition to enhanced immunity to
pathogens, regular exercise also has the potential to be
anti-inflammatory in nature, reflecting a mechanism via
which low-grade inflammation and associated CVD risk
of aging can be reduced [33, 34]. Therefore, exercise is a
potential intervention to prevent a decline in immunity,
reduce low-grade inflammation and CVD risk in breast
cancer survivors as they age.
Autonomic cardiac regulation, as determined by the
non-invasive measurement of heart rate variability
(HRV) can be used as a measure of ANS activity, specif-
ically the parasympathetic nervous system (PNS), at rest
and in response to physiological and psychological
stress. Decreased ANS activity, is reflected by a decrease
in resting HRV or HRV reactivity to stress, and reduced
ability to regulate the sympathetic nervous system
(SNS). This condition of the ANS, with a decreased
regulation of the SNS, is associated with CVD factors
such as physical inactivity, hypertension, diabetes, and
CVD. Decreased resting and reactivity HRV also occurs
in response to chronic stress and is associated with high
fatigue levels and reduce QoL [35, 36]. Recent research
indicated that autonomic dysfunction is prevalent in
cancer survivors [37]. Cancer and associated treatments
negatively impact ANS activity, contributing to increased
cardiovascular morbidity and mortality within the cancer
population [38]. These treatments could impact the
function of the ANS by damaging the nerve fibres and
interfering with messages between the brain and the
ANS [39–41]. This occurs by a combination of sympa-
thetic overactivity and parasympathetic underactivity
negatively impacting health by causing adverse effects
such as hypertension and CVD [42, 43]. Chemotherapy
could potentially impact acetylcholine levels [44] directly
impacting the PNS, suggesting that the vagus nerve
could be implicated via the same mechanism caused by
chemotherapy. These changes may be reflected in lower
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resting HRV in breast cancer survivors. The underlying
mechanisms for this change and the effect of exercise on
mitigating negative changes seen in the breast cancer
population requires further research.
Currently, the impact of exercise intensity on improv-
ing resting HRV and salivary biomarkers of stress and
mucosal immunity in cancer survivors is unclear. A bet-
ter understanding could help improve health outcomes
by reducing stress related physical changes and psycho-
logical factors experienced by breast cancer survivor’s
due diagnosis and treatment toxicity. This knowledge
will assist in informing the development of individua-
lised exercise strategies to improve health factors and re-
duce risk for CVD [45] in the cancer population. The
current pilot randomised controlled trial was designed
to explore the impact of high-intensity interval training
(HIIT) on cardiovascular fitness and markers of cardiac
regulation (HRV), sympathetic nervous system activity
(salivary (s) α-amylase (s-AA)), HPA axis (salivary corti-
sol (s-cortisol)), and mucosal immunity (salivary im-
munoglobulin A (s-IgA)) in breast cancer survivors.
Methods
Study design and participants
This study was a pilot three-arm, 12-week randomised
control trial (RCT) with pre and post measures. Partici-
pants were included in this study if they were; (1) fe-
males between the ages of 50 and 75 years, (2) sedentary
as classified by the American College of Sports Medicine
[46], (3) were within two years post cancer treatment
and (4) did not take blood pressure medication (angio-
tensin-converting enzyme inhibitors or angiotensin re-
ceptor blockers or calcium channel blockers or beta
blockers), (5) did not have brain or bone metastasis or
(6) a diagnosis of secondary cancers and (7) were able to
perform the exercise sessions on a stationary cycle erg-
ometer (Monark 828E Ergometer) [47] (Fig. 1). The Uni-
versity of Canberra Human Research Ethics committee
approved this study (13–153). This pilot study was retro-
spectively registered through the Australian New Zea-
land Clinical Trials Registry (ANZCTR): ACTR
N12620000684921.
Randomisation, stratification, concealment, and allocation
Following the baseline testing, participants were ran-
domly allocated to one of three groups: high intensity
interval training (HIIT); continuous moderate intensity
training (CMIT); or control (CON). A concealed, com-
puter generated sequence of numbers in blocks of vari-
able sizes [3, 6, 9] in a 1:1:1 ratio for the three
intervention groups stratified by age (< 60 years and ≥ 60
years) was generated by a researcher not involved
(blinded) in the study. After baseline testing a sealed en-
velope with the group allocation was given to the partici-
pant. Study participants were told the overall aim of the
study was to compare the effects of different physical ex-
ercise interventions on health-related outcomes.
Fig. 1 Consort diagram
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Intervention groups
Exercise groups
Participants in the two exercise interventions attended
the University of Canberra laboratory three times per
week for twelve weeks (up to 36 sessions). Participants
could choose from a series of scheduled timeslots where
supervision was provided across the week and where
compliance could be recorded. Each session was con-
ducted on the Monark cycle ergometer and lasted 20–
30 min depending on the allocated intervention group.
Sessions were fully supervised by an experienced
Accredited Exercise Physiologist or Accredited Exercise
Scientist. Participant’s heart rate (HR) was continuously
measured and recorded during all exercise sessions using
a heart rate monitor (Polar FT40, Finland). Rating of
perceived exertion (RPE) was monitored and recorded
throughout each session (Borg 6–20) [48]. Exercise ses-
sions started and finished with a 5-min warm up and
cool down, completed on the cycle ergometers at ~ 50%
of their maximal power (watts) achieved in the baseline
incremental exercise test.
The CMIT group cycled for 30 min in total, with 20
min at 55–65% of their maximal power. The workload
was adjusted over 12 weeks within this range to ensure
their RPE remained between 9 and 13 on the Borg scale
[49]. The HIIT group completed seven 30 s intervals (as
hard as they could) with 2 min of active recovery be-
tween each. Participants were instructed to increase
their cadence to between 95 and 115 RPM to ensure
consistent performance. Participants initially completed
four intervals in each session, and this was gradually in-
creased to achieve the target of seven intervals by week
four.
Control group
Participants in the wait listed control group (CON) were
asked to continue with their current lifestyle for 12
weeks after the baseline tests. After completion, the par-
ticipants from the CON group were offered the 12 week
fully supervised intervention.
Testing protocols
Participants were asked not to consume food or caffeine
or participate in exercise within two hours prior to pre-
and post-testing. Assessments were carried out within
the 2–4 days prior to commencement of the program
and within 2–4 days following completion. HRV and sal-
ivary biomarker measures were taken prior to cardiore-
spiratory fitness testing.
Cardiorespiratory fitness
Assessment of maximal aerobic power
A maximal graded incremental cycling test was con-
ducted to determine VO2 Peak, intervention relative
intensity and pre and post intervention fitness levels
(High-Performance Ergometer, Schoberer Rad MeBtech-
nik, Germany). Participants respired through an oro-nasal
mask (Hans-Rudolph 7450 Series V2™ Mask, CareFusion,
France), breath by breath cardiopulmonary data (Vyntus
CPX, Metabolic Cart, Jaeger, Germany) were measured to
calculate VO2Peak in the cardiopulmonary exercise test.
Throughout the test an Accredited Exercise Physiologist
monitored participants with 12-Lead electrocardiogram
(ECG). Blood pressure was assessed via sphygmomanome-
try and was recorded every two minutes.
The protocol commenced with a five minute warm up
at 20 watts [50]. Thereafter, the workload was increased
by ≤20 watts each minute [50] until three of the follow-
ing criteria [51] were reached: 1) no change in oxygen
consumption with increasing workload, 2) respiratory
exchange ratio > 1.1, 3) heart rate within 10% of age pre-
dicted maximal heart rate or, 4) inability to maintain
pedalling cadence. Participants self-selected peddling ca-
dence > 60 rpm. In addition, exercise was terminated on
the presentation of volitional fatigue, abnormal changes
in blood pressure, or ECG abnormalities.
Cardiac regulation and biomarker of stress
Heart rate variability
A Suunto watch and chest belt (Suunto model t6,
Finland) was fitted to measure R-R intervals. Each belt
was interfaced with the Suunto t6 watch for purposes of
monitoring continuous R–R intervals [52]. Each partici-
pant sat quietly on a chair in an upright position for 10
min prior to the commencement of HRV recording. Al-
though HRV is higher seated than supine, the seated
posture was selected for its practicality and convenience
[53]. R–R interval recording lasted 5 min and these were
then transferred to Kubios HRV analysis software
(Kubios heart rate variability software version 2.0; Bio-
signal Analysis and Medical Imaging Group, Department
of Physics, University of Kuopio, Kuopio, Finland) for
the analyses of time and frequency HRV domains. Par-
ticipants’ respiratory rate during the recordings was not
controlled for as there is a lack of consensus on the in-
fluence of controlled versus non-controlled breathing on
HRV parameters, particularly at rates < 10 breaths/mi-
nute [54]. The protocol was carried out in accordance
with the Task Force of the European Society of Cardi-
ology and the North American Society of Pacing and
Electrophysiology standards for measurement of short-
term HRV [55]. One of the recordings in the CON
group could not be analysed due to > 20% R-R interval
artefacts over the duration of the recording [52].
Saliva collection and analysis
Saliva samples (s-AA, s-IgA and s-cortisol) were ob-
tained using IPRO Oral Fluid Collection (OFC) kits that
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were labelled and provided to each participant. The OFC
kits collect 0.5 mL of oral fluid and contain a colour
changing volume adequacy indicator within the swab,
giving collection times typically in the range of 20–50 s
[56].
Baseline saliva samples were collected at two-time
points on the same day at home, two days before and
after the intervention commenced and ended (immedi-
ately upon waking whilst still in bed and 30min post
waking) [57]. The participants received training on the
saliva collection procedure during their first visit to the
laboratory. They were requested to adhere as closely as
possible to the standardised collection guidelines, which
was carried out in their home [57, 58]. Participants re-
corded the time each saliva sample was collected. All
samples were frozen immediately after collection in
home freezers and kept frozen until reaching the labora-
tory, upon which they were stored at − 20 °C until
analysis.
Statistical analysis
The data were analysed with a general linear mixed
model using the R package lme4 (R Core Team 2018). A
random intercept for participants was included to ac-
count for intraindividual dependencies and interindivid-
ual heterogeneity. This also allowed for individual
baseline adjustment. All models were estimated using
Restricted Maximum Likelihood. Visual inspection of re-
sidual plots did not reveal any obvious deviations from
homoscedasticity or normality. P-values were obtained
using Type II Wald F tests with Kenward-Roger degrees
of freedom as implemented in the R package car [59].
Statistical significance was determined on p ≤ 0.05, in
addition confidence intervals (CI) were assessed whether
they included zero or not. Results are reported as mean
estimates and 95% confidence intervals. The natural log
was initially calculated and analysed for HRV parameters
before the above statistical analyses were carried out. A
biofeedback manual cleanup process was carried out for
the HRV data using the Kubios protocol [60].
Results
Participants and adherence
All participants who were randomised completed the
study (n = 17). Thirty-one participants applied to be part
of the study and 14 were either not eligible (n = 10) or
failed to respond (n = 4). Participants completed baseline
testing before being randomised into the HIIT (n = 6),
CMIT (n = 5) or CON (n = 6) (Fig. 1). Participants diag-
nosed with breast cancer within the prior 24 months.
The mean age of participants was 62 ± 8 years, with a
BMI of 26.30 ± 4.39 kg/m2 (Table 1). Participants were
similar at baseline for age and treatment types (p > 0.05).
Baseline values were similar for all variables across the
three groups except for s-IgA, which was lower in the
HIIT group compared to the CON group (B = -308.23,
95%CI = [− 555.06; − 61.41]). CMIT was significantly
higher at baseline for; log very low frequency (LnVLF) (F
(2, 12) = 5.23, p = 0.02, B = 1.95, 95%CI = [0.11; 3.79])
and non-significant for log high frequency (LnHF) (F (2,
12)=1.21, p = 0.07, B = 2.33, 95%CI = [0.04; 4.62]) com-
pared to the CON group. Adherence was similar between
the exercise groups (HIIT and CMIT) (percentage of ses-
sions attended: 78.7 ± 13.2% vs 79.4 ± 12.0%; p = 0.93).
Exercise intervention
The HIIT group’s average HR during the sessions was
150 ± 9 beats per minute (bpm) during the intervals,
while the RPE was 12 ± 4. The average HR and RPE at
the end of the two-minute recovery was 125 ± 12 bpm
and 9 ± 6 bpm. The average HR during the sessions for
the CMIT group was 136 ± 16 and RPE was 13 ± 10.
Overall mean session compliance was 79% (78.7 ± 13.2%
(HIIT) vs 79.4 ± 12.0% (CMIT); p = 0.93). There were no
adverse events from the exercise intervention in this
study. The HIIT group had a significantly higher relative
HR (93.5 ± 7.1% vs. 83.9 ± 1.9%; p = 0.04) and non-
significantly higher RPE (13.6 ± 1.8 vs.12.3 ± 1.6; p =
0.09) when compared to the CMIT group at the end of
the last exercise session after the 12 weeks of training.
Cardiovascular fitness
A significant difference (F2,12 = 6.53, p = 0.01) was seen
in VO2 Peak from pre to post intervention for the HIIT
group. A 19.3% (B = 3.98, 95%CI = [1.88; 6.02]) increase
for HIIT and a 5.6% (B = 1.96, 95%CI = [− 0.11; 4.03]) in-
crease for the CMIT group, was observed compared to




Pre and post changes for HRV measures in all three
groups are shown in Table 2. Individual changes for
LnRMSSD are shown in Fig. 2. There were no significant
changes in HRV measures from pre to post for any of
the groups (all p > 0.05). LnVLF was significantly higher
for the CMIT group compared to the other groups, both
pre and post intervention (B = 1.95, 95%CI = [0.11;
3.79]).
Salivary biomarkers
For s-IgA (30min post waking) there were no significant
differences over time or between groups (p > 0.1, see Fig. 3
a a for individual responses).
Overall, there was a slight increase from pre to post
intervention (B = 163.65, 95%CI = [− 56.70; 384.28], p =
0.03) in s-cortisol expressed as percent change from
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waking to 30min post waking (Fig. 3b). There were two
participants within the exercise groups who demon-
strated an improvement in their s-AA waking response
from baseline to post intervention (Fig. 3c). However, no
statistically significant group changes were observed for
s-AA (p > 0.2).
Discussion
The present study investigated the effect of exercise in-
tensity on cardiovascular fitness and was the first study
to measure this in combination with cardiac regulation
(HRV) and salivary biomarkers of stress including muco-
sal immunity in breast cancer survivors. High intensity
interval training improved cardiovascular fitness com-
pared to CMIT providing preliminary support for this
short and intense dose of exercise to improve health
outcomes in breast cancer survivors. Non-significant im-
provements in cardiac vagal activity, and sympathetic
nervous system responses in individuals with outlying
baseline values (compared to healthy population) were
detected in response to the exercise intervention, poten-
tially reducing risk of common diseases in the cancer
population such as CVD. These changes should be fur-
ther investigated in longer and larger scale RCT’s.
There are limited studies reporting changes in s-AA in
breast cancer, however, it has been proposed that breast
cancer survivors display elevated patterns of alpha-
amylase in both diurnal and acute profiles compared to
healthy women [61, 62]. Only one study to date has re-
ported changes in s-AA as a marker of stress across the
chemotherapy treatment regime in two groups of breast
cancer patients [63]. This study found an increase in pa-
tient stress levels as they progressed through the chemo-
therapy treatment cycle, and in addition in-patient stress
was higher than out-patient stress [63]. Typically, s-AA
would decrease significantly in the 30min after waking,
indicating a healthy response [64]. In the current study
two individuals (one in the HIIT group and one in the
CMIT group, Fig. 3c), did not exhibit normal s-AA
waking responses. Both started the intervention with
outlying, abnormal s-AA waking responses (> 95% CI)
where their baseline s-AA increased by > 600% 30min
post-waking. Post-intervention these two individuals ex-
hibited improved (normal response is ~ 50% decrease in
s-AA 30min post waking) s-AA waking responses. This
Table 1 Participant Characteristics
Control (n = 6) CMIT (n = 5) HIIT (n = 6)
Age (y) 61 ± 7.92 65 ± 7.68 60 ± 8.12
Height (cm) 163.5 ± 5.20 165.6 ± 5.59 165.6 ± 5.78
Weight (kg) 75.63 ± 7.71 68.80 ± 11.48 69.48 ± 16.07
BMI (kg/m2) 28.5 ± 4.53 24.95 ± 2.48 25.23 ± 5.22
Body Fat (%) 45.52 ± 9.32 37.76 ± 5.61 33.60 ± 10.03
VO2 (ml/min
− 1/kg− 1) 20.90 ± 3.10 20.74 ± 3.71 19.52 ± 3.89
Treatment
Surgery 0 1 (20%) 0
Radiation 0 1 (20%) 0
Surgery + chemotherapy 1 (17%) 0 0
Surgery + radiation 2 (33%) 3 (60%) 3 (50%)
Surgery + chemotherapy + radiation 3 (50%) 0 3 (50%)
Table 2 Heart rate variability changes from pre to post exercise intervention
CON (n = 6) CMIT (n = 5) HIIT (n = 6)
Pre Post Pre Post Pre Post
LnVLF 2.98 ± 0.69 2.37 ± 1.03 4.93 ± 1.11 5.06 ± 1.00* 3.78 ± 0.90 3.86 ± 2.74
LnLF 4.88 ± 0.92 3.93 ± 1.08 6.75 ± 0.73 6.85 ± 0.67 4.72 ± 2.14 5.19 ± 2.85
LnHF 4.38 ± 0.82 3.83 ± 0.75 6.71 ± 1.26 7.07 ± 0.78 4.48 ± 2.07 5.50 ± 3.13
LnLF/HF 0.51 ± 0.74 0.10 ± 0.59 0.04 ± 1.23 − 0.22 ± 0.89 0.24 ± 1.43 − 0.31 ± 0.55
Mean RR (m/s) 845.70 ± 76.01 815.66 ± 58.21 902.69 ± 37.36 792.69 ± 90.86 834.07 ± 147.40 848.11 ± 165.45
Mean HR* (b/min) 71.37 ± 6.28 73.83 ± 5.07 66.61 ± 2.84 76.47 ± 8.47 74.12 ± 14.88 73.24 ± 15.64
LnRMSSD 3.01 ± 0.90 2.95 ± 0.96 3.94 ± 0.51 4.29 ± 0.60 3.09 ± 0.63 3.35 ± 1.62
* time effect, Log (Ln), LnVLF very low frequency, LnLF low frequency, LnHF high frequency, LnLF/HF low frequency/high frequency, RR measure between the R
waves, LnRMSSD root mean square of successive difference of R-R interval
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indicates a positive change after an exercise intervention
which should be further explored. The current study ob-
served one individual in the HIIT group post interven-
tion with an increase in s-AA at 30 min post waking.
This result could suggest further disease or that the
intervention was not long enough to exhibit a response
for this individual, or more likely an error in the self-
administered saliva collection test [64].
The expected cortisol diurnal rhythm is an initial in-
crease in the first 30–60 min post waking, followed by
further increases in the morning, before progressively
declining into the evening. HPA dysregulation indicated
by abnormal, flatter diurnal cortisol patterns (cortisol
levels which do not rise during the morning or decrease
in the evening) is associated with the incidence and pro-
gression of breast cancer [65, 66]. In some breast cancer
survivors, blunted waking or diurnal cortisol response,
across the day have been reported [67]. Importantly, in
the current study a slight increase (non-significant) in s-
cortisol (percent change) was seen 30 mins post waking
in the exercise groups, this may signify improved HPA
axis activity post intervention. This mechanism has sig-
nificant clinical value because it represents a reduction
in stress levels with regular exercise [68] in the cancer
population and should be investigated further. Objective
physiological stress markers are not commonly mea-
sured or taken into consideration in clinical practice to
assess patients or prescribe individual exercise but could
be considered as it is an early marker of the progression
of future disease.
Salivary immunoglobulin A is an antigen specific anti-
body that mediates primary immune system responses
and has a protective role against bacterial, viral and
protozoal infections of the mucosa [69]. Disruptions to
the immune system are highly correlated with cancer,
obesity and CVD [70] but there are a lack of studies ex-
ploring mucosal immune function in breast cancer pa-
tients and survivors. Also the interaction of a diagnosis
of cancer causes significant stress contributing to the re-
duction in immune function [71], increasing the risk for
further disease. It has been advised that high intensity
overtraining reduces s-IgA levels, weakening the im-
mune response [72], instigating a risk with participating
in HIIT, however, in the current study mucosal immun-
ity was maintained in the exercise groups and sIgA did
not increase.
Autonomic nervous system dysfunction, typically repre-
sented as low HRV, is prevalent in the cancer population
(young adults with cancer and breast cancer) [38, 73], po-
tentially contributing to treatment related side effects,
such as cardiovascular decline, inflammation, increased fa-
tigue and decreased QoL, [38, 74] and increased risk of
CVD [75]. For HRV, the time domain, root mean square
of successive difference of R-R intervals (RMSSD), and fre-
quency domain, HF band, represents cardiac vagal activity
[54, 76], with higher levels reflecting higher HRV and en-
hanced ANS activity. The LF (low frequency) band is asso-
ciated with baroreflex activity and the bilateral effect of
sympathetic and vagal activity on the sinus node impact-
ing on levels of stress experienced. It has been reported
that cancer survivors, and in particular those who were
older, expressed significantly lower LnRSMMD levels
when compared to healthy individuals [74]. In the current
study, baseline LnRMSSD was slightly below the reported
Fig. 2 Individual responses from pre to post intervention for each group (CON, CMIT, HIIT) for heart rate variability time domains LnRMSSD in m/
s2. Estimated group means, and 95% confidence intervals are shown in grey
Toohey et al. BMC Cancer          (2020) 20:787 Page 7 of 11
Fig. 3 (See legend on next page.)
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healthy levels [77], and rose to healthy norms [74] in the
exercise groups post intervention (Fig. 2). The changes ob-
served in this study suggest that exercise improved ANS
function, specifically vagal activity, potentially decreasing
treatment related side effects and the risk of CVD.
A limitation of the current study was that participants
who did not undergo chemotherapy were randomly allo-
cated into the CMIT group. This may explain the differ-
ences observed in baseline HRV variables (in the
chemotherapy and non-chemotherapy groups), consider-
ing treatment regimes when stratifying participants in
future studies would be advantageous. Comparable to
the current study and studies prior on cancer survivors,
chemotherapy could potentially be involved in the devel-
opment of abnormalities in the ANS [78] although in
the current study there were no participants currently
undergoing active treatment. Due to the low numbers,
caution must be taken regarding the generalisability of
the findings to all cancer survivors. A further limitation
was that saliva collection was not observed relying on
participants to remember the protocol and self-report
timings. Despite these limitations, clinically important
results were noted which have practical application and
further clinical trials would be useful to confirm the
results.
Conclusion
This study demonstrated that HIIT improved cardiovas-
cular fitness (compared to CMIT) in breast cancer survi-
vors and also improved cardiac vagal activity, and
sympathetic nervous system responses in individuals
with outlying baseline values, potentially reducing risk of
diseases such as CVD. Those participants within the
normal ranges at baseline (HPA-axis, ANS and mucosal
immunity) remained that way and were not negatively
impacted by exercise at higher intensities. High-intensity
interval training was safe and effective for breast cancer
survivors to participate in with promising results as im-
proved health outcomes were observed. Future exercise
guidelines for cancer survivors should consider the use
of HIIT to improve levels of fitness.
Abbreviations
HRV: Heart rate variability; HPA: Hypothalamic-pituitary-adrenal;
IgA: Immunoglobulin; HIIT: High intensity interval training; CMIT: Continuous
moderate intensity training; CON: Control; VO2peak: Peak oxygen uptake;
Ln: Log; VLF: Very low frequency; LF: Low frequency; HF: High frequency;
RR: Measure between the R waves; RMSSD: Root mean square of successive
difference of R-R intervals; CVD: Cardiovascular disease; QoL: Quality of life;
ANS: Autonomic nervous system; PNS: Parasympathetic nervous system;
SNS: Sympathetic nervous system; RCT: Randomised controlled trial
Acknowledgements
Thank you to Associate Professor Ben Rattray, Associate Professor Disa Pryor
and Ms. Ashley Ikin for your assistance with testing and supervision of the
participants in this study.
Authors’ contributions
KT, SS, KP, JC conceived and designed research. KT, JN and CQ conducted
experiments. MW, KT and AM analysed data. KT wrote the manuscript. All
authors edited, read and approved the manuscript.
Funding
The authors declare that there was no funding received for this project.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
The University of Canberra Human Research Ethics committee approved this
study (13–153), written consent was obtained for study participants.
Consent for publication
No identified individual data was used. All participants signed an informed
consent to use their de-identified data.
Competing interests
The authors declare that they have no competing interests.
Author details
1Research Institute for Sport and Exercise, University of Canberra, Canberra
2601, Australia. 2Discipline of Sport and Exercise Science, Faculty of Health,
University of Canberra, Canberra 2601, Australia. 3Health Research Institute,
University of Canberra, Canberra 2601, Australia. 4Prehabilitation, Activity,
Cancer, Exercise and Survivorship (PACES) Research Group, University of
Canberra, Canberra 2601, Australia. 5School of Health Sciences, University of
KwaZulu-Natal, Durban 400, South Africa. 6Statistical Consulting Unit,
Australian National University, Canberra 2600, Australia.
Received: 16 June 2020 Accepted: 12 August 2020
References
1. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, et al.
Exercise and risk of cardiovascular events in women with nonmetastatic
breast cancer. J Clin Oncol. 2016;34(23):2743.
2. Toohey KP, Kate, McKune, Andrew, Cooke, Julie, DuBose, Katrine, Yip,
Desmond, Craft, Paul. Does low volume high-intensity interval training elicit
superior benefits to continuous low to moderate-intensity training in cancer
survivors? World J Clin Oncol. 2018;9(1):1.
3. Giese-Davis J, Wilhelm FH, Conrad A, Abercrombie HC, Sephton S, Yutsis M,
et al. Depression and stress reactivity in metastatic breast cancer.
Psychosom Med. 2006;68(5):675–83.
4. Paolucci T, Bernetti A, Bai AV, Capobianco SV, Bonifacino A, Maggi G, et al.
The recovery of reaching movement in breast cancer survivors: two different
rehabilitative protocols in comparison. Eur J Physical Rehabil Med. 2020.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;
69(1):7–34.
(See figure on previous page.)
Fig. 3 a 30 min post waking s-IgA individual responses from pre to post intervention for each group (CON, CMIT, HIIT). Estimated group means,
and 95% confidence intervals are shown in grey. b Waking to 30min post-waking (percent change) s-cortisol individual responses from pre to
post intervention for each group (CON, CMIT, HIIT). Estimated group means, and 95% confidence intervals are shown in grey. c Waking to 30 min
post-waking (percent change) s-AA individual responses from pre to post intervention for each group (CON, CMIT, HIIT). Estimated group means,
and 95% confidence intervals are shown in grey
Toohey et al. BMC Cancer          (2020) 20:787 Page 9 of 11
6. Mattiuzzi C, Lippi G. Cancer statistics: a comparison between world health
organization (WHO) and global burden of disease (GBD). Eur J Pub Health.
2019.
7. Michelotti A, Invernizzi M, Lopez G, Lorenzini D, Nesa F, De Sire A, et al.
Tackling the diversity of breast cancer related lymphedema: perspectives on
diagnosis, risk assessment, and clinical management. Breast. 2019;44:15–23.
8. Koehler LA, Haddad TC, Hunter D, Tuttle TM. Axillary web syndrome
following breast cancer surgery: symptoms, complications, and
management strategies. Breast Cancer. 2019;11:13.
9. Valente SA, Liu Y, Upadhyaya S, Tu C, Pratt DA. The effect of wound
complications following mastectomy with immediate reconstruction on
breast cancer recurrence. Am J Surg. 2019;217(3):514–8.
10. de Sire A, Invernizzi M, Lippi L, Cisari C, Özçakar L, Franchignoni F. Blurred
lines between axillary web syndrome and Mondor’s disease after breast
cancer surgery: a case report. Ann Phys Rehabil Med. 2019;63(4):365–7.
11. Dinas K, Kalder M, Zepiridis L, Mavromatidis G, Pratilas G. Axillary web
syndrome: incidence, pathogenesis, and management. Curr Probl Cancer.
2019;43(6):100470.
12. Yang S, Chu S, Gao Y, Ai Q, Liu Y, Li X, et al. A narrative review of Cancer-
related fatigue (CRF) and its possible pathogenesis. Cells. 2019;8(7):738.
13. Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, et al.
Patient-reported and clinician-reported chemotherapy-induced peripheral
neuropathy in patients with early breast cancer: current clinical practice.
Cancer. 2019;125(17):2945–54.
14. Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of
supervised exercise on cancer-related fatigue in breast cancer survivors: a
systematic review and meta-analysis. BMC Cancer. 2015;15(1):77.
15. Dobek J, Winters-Stone KM, Bennett JA, Nail L. Musculoskeletal changes
after 1 year of exercise in older breast cancer survivors. J Cancer Surviv.
2014;8(2):304–11.
16. Toohey K, Pumpa K, McKune A, Cooke J, Semple S. High-intensity exercise
interventions in cancer survivors: a systematic review exploring the impact
on health outcomes. J Cancer Res Clin Oncol. 2018;144(1):1–12.
17. Tsigos C, Chrousos GP. Hypothalamic–pituitary–adrenal axis, neuroendocrine
factors and stress. J Psychosom Res. 2002;53(4):865–71.
18. Kivlighan KT, Granger DA. Salivary α-amylase response to competition:
relation to gender, previous experience, and attitudes.
Psychoneuroendocrinology. 2006;31(6):703–14.
19. Campkin M. Stress management in primary care. Fam Pract. 2000. 98-99 p.
20. Tracey KJJN. The inflammatory reflex. Nat. 2002;420(6917):853–9.
21. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of
cancer recurrence. J Cancer Surviv. 2015;9(3):481–91.
22. Stewart B, Wild CP. World cancer report 2014. Health. 2017.
23. Sephton SE, Dhabhar FS, Keuroghlian AS, Giese-Davis J, McEwen BS, Ionan
AC, et al. Depression, cortisol, and suppressed cell-mediated immunity in
metastatic breast cancer. Brain Behav Immun. 2009;23(8):1148–55.
24. Zitvogel L, Tesniere A, GJNRI K. Cancer despite immunosurveillance:
immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):
715–27.
25. Invernizzi M, Runza L, De Sire A, Lippi L, Blundo C, Gambini D, et al.
Integrating augmented reality tools in breast cancer related lymphedema
prognostication and diagnosis. JoVE. 2020;(156):e60093.
26. De Sire A, Losco L, Cigna E, Lippi L, Gimigliano F, Gennari A, et al. Three-
dimensional laser scanning as a reliable and reproducible diagnostic tool in
breast cancer related lymphedema rehabilitation: a proof-of-principle study.
Eur Rev Med Pharmacol Sci. 2020;24(8):4476–85.
27. Paolucci T, Bernetti A, Bai AV, Segatori L, Monti M, Maggi G, et al. The sequelae
of mastectomy and quadrantectomy with respect to the reaching movement
in breast cancer survivors: evidence for an integrated rehabilitation protocol
during oncological care. Support Care Cancer. 2020:1–10.
28. Invernizzi M, Lopez G, Michelotti A, Venetis K, Sajjadi E, Mattos-Arruda D,
et al. Integrating biological advances into the clinical Management of Breast
Cancer Related Lymphedema. Front Oncol. 2020;10:422.
29. Nieman DC, Henson DA, Gusewitch G, Warren BJ, Dotson RC, Butterworth
DE, et al. Physical activity and immune function in elderly women. Med Sci
Sports Exerc. 1993;25(7):823–31.
30. Nieman DC. Exercise and resistance to infection. Can J Physiol Pharmacol.
1998;76(5):573–80.
31. Dinh HC, Beyer I, Mets T, Onyema O, Njemini R, Renmans W, et al. Effects of
physical exercise on markers of cellular immunosenescence: a systematic
review. Calcif Tissue Int. 2017;100(2):193–215.
32. Akimoto T, Kumai Y, Akama T, Hayashi E, Murakami H, Soma R, et al. Effects
of 12 months of exercise training on salivary secretory IgA levels in elderly
subjects. Br J Sports Med. 2003;37(1):76–9.
33. Franceschi C, Garagnani P, Parini P, Giuliani C, AJNRE S. Inflammaging: a
new immune–metabolic viewpoint for age-related diseases. Nat Rev
Endocrinol. 2018;14(10):576–90.
34. Dethlefsen C, Pedersen KS, PJBcr H. Treatment Every exercise bout matters:
linking systemic exercise responses to breast cancer control. Breast Cancer
Res Treat. 2017;162(3):399–408.
35. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction:
time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2.
36. Thornton LM, Andersen BL, Blakely WP. The pain, depression, and fatigue
symptom cluster in advanced breast cancer: Covariation with the
hypothalamic–pituitary–adrenal axis and the sympathetic nervous system.
Health Psychol. 2010;29(3):333.
37. Arab C, Dias DPM, de Almeida Barbosa RT, de Carvalho TD, Valenti VE,
Crocetta TB, et al. Heart rate variability measure in breast cancer patients
and survivors: a systematic review. Psychoneuroendocrinology. 2016;68:57–68.
38. Adams SC, Schondorf R, Benoit J, Kilgour RD. Impact of cancer and
chemotherapy on autonomic nervous system function and cardiovascular
reactivity in young adults with cancer: a case-controlled feasibility study.
BMC Cancer. 2015;15(1):414.
39. Hirvonen HE, Salmi TT, Heinonen E, Antila KJ, Välimäkiy IA. Vincristine
treatment of acute lymphoblastic leukemia induces transient autonomic
cardioneuropathy. Cancer. 1989;64(4):801–5.
40. Hrushesky WJ, Fader DJ, Berestka JS, Sommer M, Hayes J, Cope FO.
Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-
induced cardiomyopathy. Circulation. 1991;84(2):697–707.
41. Ekholm EM, Salminen EK, Huikuri HV, Jalonen J, Antila KJ, Salmi TA, et al.
Impairment of heart rate variability during paclitaxel therapy. Cancer. 2000;
88(9):2149–53.
42. Mark AL. The sympathetic nervous system in hypertension: a potential long-
term regulator of arterial pressure. J Hypertens Suppl. 1996;14(5):S159–65.
43. Thayer JF, RDJBp L. The role of vagal function in the risk for cardiovascular
disease and mortality. Biol Psychol. 2007;74(2):224–42.
44. Keeney JT, Ren X, Warrier G, Noel T, Powell DK, Brelsfoard JM, et al.
Doxorubicin-induced elevated oxidative stress and neurochemical
alterations in brain and cognitive decline: protection by MESNA and
insights into mechanisms of chemotherapy-induced cognitive impairment
(“chemobrain”). Oncotarget. 2018;9(54):30324.
45. Caro-Morán E, Fernández-Lao C, Galiano-Castillo N, Cantarero-Villanueva I,
Arroyo-Morales M, Díaz-Rodríguez L. Heart rate variability in breast cancer
survivors after the first year of treatments: a case-controlled study. Biol Res
Nurs. 2016;18(1):43–9.
46. ACSM. ACSM’s guidelines for exercise testing and prescription: Lippincott
Williams & Wilkins; 2013.
47. Lakomy H. Measurement of work and power output using friction-loaded
cycle ergometers. Ergonomics. 1986;29(4):509–17.
48. Borg G, Linderholm H. Perceived exertion and pulse rate during graded
exercise in various age groups. J Intern Med. 1967;181(S472):194–206.
49. Williams N. The Borg rating of perceived exertion (RPE) scale. Occup Med.
2017;67(5):404–5.
50. Murrell CJ, Cotter JD, Thomas KN, Lucas SJ, Williams MJ, Ainslie PN. Cerebral
blood flow and cerebrovascular reactivity at rest and during sub-maximal
exercise: effect of age and 12-week exercise training. Age. 2013;35(3):905–20.
51. Ainslie PN, Cotter JD, George KP, Lucas S, Murrell C, Shave R, et al. Elevation
in cerebral blood flow velocity with aerobic fitness throughout healthy
human ageing. J Physiol. 2008;586(16):4005–10.
52. Sookan T, AJJCjoA MK. Heart rate variability in physically active individuals:
reliability and gender characteristics. Cardiovasc J Afr. 2012;23(2):67.
53. Acharya UR, Kannathal N, Hua LM, Yi LM. Study of heart rate variability
signals at sitting and lying postures. J Bodyw Mov Ther. 2005;9(2):134–41.
54. Tarvainen MP, Niskanen J-P, Lipponen JA, Ranta-Aho PO, Karjalainen PA.
Kubios HRV–heart rate variability analysis software. Comput Methods Prog
Biomed. 2014;113(1):210–20.
55. Camm AJ, Malik M, Bigger J, Breithardt G, Cerutti S, Cohen RJ, et al. Heart
rate variability. Standards of measurement, physiological interpretation, and
clinical use. Eur Heart J. 1996;17(3):354–81.
56. Jehanli A, Dunbar J, Skelhorn S, editors. Development and validation of an
oral fluid collection device and its use in the immunoassay of salivary
Toohey et al. BMC Cancer          (2020) 20:787 Page 10 of 11
steroids and immunoglobulins in sports persons. Proceedings 10th
Symposium Intl Soc Ex Imunol; 2011.
57. McKune AJ, Bach CW, Semple SJ, Dyer BJ. Salivary cortisol and α-amylase
responses to repeated bouts of downhill running. Am J Hum Biol. 2014;
26(6):850–5.
58. DuBose KD, McKune AJ. The relationship between objectively measured
physical activity, salivary cortisol, and the metabolic syndrome score in girls.
Pediatr Exerc Sci. 2014;26(3):221–30.
59. Fox J, Weisberg S. An R companion to applied regression: sage publications;
2011.
60. Kaufmann T, Sütterlin S, Schulz SM, Vögele C. ARTiiFACT: a tool for heart
rate artifact processing and heart rate variability analysis. Behav Res
Methods. 2011;43(4):1161–70.
61. Wan C, Couture-Lalande MÈ, Narain TA, Lebel S, Bielajew C. Salivary Alpha-
Amylase Reactivity in Breast Cancer Survivors. Int J Environ Res Public
Health. 2016;13(4):353.
62. Strahler J, Mueller A, Rosenloecher F, Kirschbaum C, Rohleder N. Salivary
alpha-amylase stress reactivity across different age groups. Psychophysiol.
2010;47(3):587–95.
63. Sultan A, Pati AK, Chaudhary V, Parganiha A. Circadian rhythm
characteristics of salivary alpha-amylase – a potential stress marker, in breast
cancer in- and out-patients: a follow-up study, Biol Rhythm Res. 2018;49:5:
680–96.
64. Nater UM, Rohleder N, Schlotz W, Ehlert U, Kirschbaum C. Determinants of
the diurnal course of salivary alpha-amylase. Psychoneuroendocrinology.
2007;32(4):392–401.
65. Antonova L, Aronson K, Mueller CR. Stress and breast cancer: from
epidemiology to molecular biology. Breast Cancer Res. 2011;13(2):208.
66. Zeitzer JM, Nouriani B, Rissling MB, et al. Aberrant nocturnal cortisol and
disease progression in women with breast cancer. Breast Cancer Res Treat.
2016;158(1):43–50.
67. Couture-Lalande M-È, Lebel S, CJBCM B. Analysis of the cortisol diurnal
rhythmicity and cortisol reactivity in long-term breast cancer survivors
Marie-Ève Couture-Lalande, Sophie Lebel, and Catherine Bielajew, Breast
Cancer Management. 2014;3(6):465–76.
68. Spiegel I, Peles E. A new player in CNS myelination. Neuron. 2006;49(6):777–
8.
69. Bishop NC, Gleeson M. Acute and chronic effects of exercise on markers of
mucosal immunity. Front Biosci (Landmark Ed). 2009;14:4444-56.
70. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven
biomarkers to guide immune checkpoint blockade in cancer therapy. Nat
Rev Cancer. 2016;16(5):275–87.
71. Dhabhar FS. Effects of stress on immune function: the good, the bad, and
the beautiful. Immunol Res. 2014;58(2-3):193–210.
72. Shephard RJ, Shek PN. Heavy exercise, nutrition and immune function: is
there a connection?. Int J Sports Med. 1995;16(8):491–7.
73. Ahmed MN, Carpenter S. Autonomic neuropathy and carcinoma of the
lung. Can Med Assoc J. 1975;113(5):410-12.
74. De Couck M, Gidron Y. Norms of vagal nerve activity, indexed by heart rate
variability, in cancer patients. Cancer Epidemiol. 2013;37(5):737–41.
75. Scott JM, Jones LW, Hornsby WE, Koelwyn GJ, Khouri MG, Joy AA, et al.
Cancer therapy-induced autonomic dysfunction in early breast cancer:
implications for aerobic exercise training. Int J Cardiol. 2014;171(2):e50–e1.
76. Sztajzel J. Heart rate variability: a noninvasive electrocardiographic method
to measure the autonomic nervous system. Swiss Med Wkly. 2004;134(35–
36):514–22.
77. Shaffer F, Ginsberg J. An overview of heart rate variability metrics and
norms. Front Public Health. 2017;5:258.
78. Giese-Davis J, Wilhelm FH, Tamagawa R, Palesh O, Neri E, Taylor CB, Kraemer
HC, Spiegel D. Higher vagal activity as related to survival in patients with
advanced breast cancer: an analysis of autonomic dysregulation.
Psychosomatic medicine. 2015;77(4):346–55.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Toohey et al. BMC Cancer          (2020) 20:787 Page 11 of 11
